At time of diagnosis of index cancer | Â | Â | Â | Â |
---|---|---|---|---|
Variable N (%) | Total (N = 3394) | HR-positive (n = 2015) | HR-negative (n = 1379) | P-value |
Age, mean (se), y | 52.48 (0.21) | 52.41 (0.29) | 52.59 (0.32) | Â |
Age category, N, (%) | Â | Â | Â | <.001 |
0 to <50 | 1,514 (45) | 931 (46) | 583 (42) | Â |
50 to <70 | 1,547 (46) | 865 (43) | 682 (49) | Â |
70+ | 333 (10) | 219 (11) | 114 (8) | Â |
Race/Ethnicity, N, (%) | Â | Â | Â | 0.030 |
African-American | 259 (8) | 135 (7) | 124 (9) | Â |
Caucasian | 2,693 (79) | 1,627 (81) | 1,066 (77) | Â |
Hispanic | 262 (8) | 155 (8) | 107 (8) | Â |
Asian Pacific Island | 126 (4) | 64 (3) | 62 (5) | Â |
American Indian | 10 (<1) | 4 (<1) | 6 (<1) | Â |
Other | 16 (<1) | 10 (1) | 6 (<1) | Â |
Unknown | 28 (1) | 20 (1) | 8 (1) | Â |
Menopausal Status, N, (%) | Â | Â | Â | 0.001 |
Premenopausal | 1,569 (46) | 978 (49) | 591 (43) | Â |
Postmenopausal | 1,825 (54) | 1,037 (51) | 788 (57) | Â |
Body Mass Index kg/m2, N, (%) | Â | Â | Â | 0.512 |
<18.5 kg/m2 (Underweight) | 52 (2) | 34 (2) | 18 (1) | Â |
18.5 to <25 kg/m2 (Normal) | 1,263 (37) | 750 (37) | 513 (37) | Â |
25 to <30 kg/m2 (Obese) | 913 (27) | 554 (27) | 359 (26) | Â |
>30 kg/m2 (Severely Obese) | 884 (26) | 506 (25) | 378 (27) | Â |
Missing/unknown | 282 (8) | 171 (8) | 111 (8) | Â |
Co-morbidity score, N, (%) | Â | Â | Â | 0.958 |
0 | 2,713 (80) | 1,609 (80) | 1,104 (80) | Â |
1 | 452 (13) | 271 (13) | 181 (13) | Â |
2+ | 229 (7) | 135 (7) | 94 (7) | Â |
Method of detection, N, (%) | Â | Â | Â | <.001 |
Abnormal screening mammogram | 1,209 (36) | 755 (37) | 454 (33) | Â |
Symptom | 2,012 (59) | 1,175 (58) | 837 (61) | Â |
Other | 147 (4) | 67 (3) | 80 (6) | Â |
Unknown | 26 (1) | 18 (1) | 8 (1) | Â |
T stage, category, N, (%) | Â | Â | Â | <.001 |
T1 | 1,753 (52) | 1,103 (55) | 650 (47) | Â |
T2 | 1,150 (34) | 691 (34) | 459 (33) | Â |
T3 | 244 (7) | 129 (6) | 115 (8) | Â |
T4 | 197 (6) | 73 (4) | 124 (9) | Â |
Unknown | 50 (1) | 19 (1) | 31 (2) | Â |
Nodal status, N, (%) | Â | Â | Â | <.001 |
Positive | 1,623 (48) | 907 (45) | 716 (52) | Â |
Negative | 1,757 (52) | 1,101 (55) | 656 (48) | Â |
Unknown | 14 (<1) | 7 (<1) | 7 (<1) | Â |
AJCC stage, N, (%) | Â | Â | Â | <.001 |
I | 1,187 (35) | 772 (38) | 415 (30) | Â |
II | 1,467 (43) | 887 (44) | 580 (42) | Â |
III | 740 (22) | 356 (18) | 384 (28) | Â |
Histologic grade, N, (%) | Â | Â | Â | <.001 |
Low/Intermediate | 907 (27) | 719 (36) | 188 (14) | Â |
High | 2,324 (68) | 1,211 (60) | 1,113 (81) | Â |
Unknown | 163 (5) | 85 (4) | 78 (6) | Â |
Histology, N, (%) | Â | Â | Â | <.001 |
Invasive ductal | 3,101 (91) | 1,772 (88) | 1,329 (97) | Â |
Invasive lobular | 105 (3) | 89 (4) | 16 (1) | Â |
Mixed ductal and lobular | 139 (4) | 120 (6) | 19 (1) | Â |
Other | 49 (1) | 34 (2) | 15 (1) | Â |
LVI, N, (%) | Â | Â | Â | 0.630 |
Presence | 1,164 (34) | 678 (34) | 486 (35) | Â |
Absence | 2,113 (62) | 1,267 (63) | 846 (61) | Â |
Unknown | 117 (3) | 70 (3) | 47 (3) | Â |
EIC, N, (%) | Â | Â | Â | 0.536 |
Presence | 606 (18) | 353 (18) | 253 (18) | Â |
Absence | 2,788 (82) | 1,662 (82) | 1,126 (82) | Â |
In patients with documented recurrence | Â | Â | Â | Â |
Variable | Total N = 458 | HR-positive N = 208 | HR-negative N = 250 | P -value |
Disease free interval median (range), y | 1.95 (7.69) | 2.24 (7.69) | 1.70 (7.08) | Â |
Age, mean (se), y | 50.95 (0.60) | 50.39 (0.94) | 51.41 (0.78) | Â |
Race/Ethnicity, N, (%) | Â | Â | Â | 0.644 |
African-American | 51 (11) | 21 (10) | 30 (12) | Â |
Caucasian | 358 (78) | 166 (80) | 192 (77) | Â |
Hispanic | 31 (7) | 12 (6) | 19 (8) | Â |
Asian Pacific Island | 12 (3) | 6 (3) | 6 (2) | Â |
American Indian | 1 (<1) | 1 (<1) | 0 (0) | Â |
Other | 4 (1) | 1 (<1) | 3 (1) | Â |
Unknown | 1 (<1) | 1 (<1) | 0 (0) | Â |
Menopausal status at time of diagnosis of index cancer, N, (%) | Â | Â | Â | 0.207 |
Premenopausal | 223 (49) | 108 (52) | 115 (46) | Â |
Postmenopausal | 235 (51) | 100 (48) | 135 (54) | Â |
Co-morbidity score at time of diagnosis of index cancer, N, (%) | Â | Â | Â | 0.437 |
0 | 371 (81) | 166 (80) | 205 (82) | Â |
1 | 57 (12) | 25 (12) | 32 (13) | Â |
2+ | 30 (7) | 17 (8) | 13 (5) | Â |
AJCC stage at time of diagnosis of index cancer, N, (%) | Â | Â | Â | 0.437 |
I | 77 (17) | 36 (17) | 41 (16) | Â |
II | 188 (41) | 91 (44) | 97 (39) | Â |
III | 193 (42) | 81 (39) | 112 (45) | Â |
Histologic grade at time of diagnosis of index cancer, N, (%) | Â | Â | Â | 0.016 |
Low/Intermediate | 65 (14) | 40 (19) | 25 (10) | Â |
High | 379 (83) | 163 (79) | 216 (86) | Â |
Unknown | 14 (3) | 5 (2) | 9 (4) | Â |